May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Estimated Incidence of Open–angle Glaucoma in the United Kingdom Using GPRD Database
Author Affiliations & Notes
  • B. Scassellati–Sforzolini
    Ophthalmology, Pfizer, San Diego, CA
  • B. Scassellati–Sforzolini
    Ophthalmology, Pfizer, San Diego, CA
  • S. Zhou
    Worldwide Outcomes Research, Pfizer, Peapack, NJ
  • S. Zhou
    Worldwide Outcomes Research, Pfizer, Peapack, NJ
  • R. Althin
    Worldwide Outcomes Research, Pfizer, High Wycombe, United Kingdom
  • Footnotes
    Commercial Relationships  B. Scassellati–Sforzolini, Pfizer Inc. F; B. Scassellati–Sforzolini, None; S. Zhou, None; S. Zhou, None; R. Althin, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 4488. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      B. Scassellati–Sforzolini, B. Scassellati–Sforzolini, S. Zhou, S. Zhou, R. Althin; Estimated Incidence of Open–angle Glaucoma in the United Kingdom Using GPRD Database . Invest. Ophthalmol. Vis. Sci. 2004;45(13):4488.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose:To determine the incidence of open–angle glaucoma (OAG) in the United Kingdom. Methods:: The population at risk included patients with General Practice Research Database records for ≥1 year before and ≥1 year after 1/1/1997. Newly diagnosed OAG patients were those with records having medical codes for OAG, excluding patients who had undergone laser peripheral iridotomy or iridectomy. Incidence of definite/probable OAG: number of newly diagnosed OAG patients / number of patient–years at risk. Incidence of definite OAG: number of newly diagnosed OAG patients prescribed an IOP–lowering agent / number of patient–years at risk. Results:In the 1,874,973 participants with 5,750,530 patient–years at risk, 6295 newly diagnosed cases of definite/probable OAG and 4548 cases of definite OAG occurred. The incidence of definite/probable OAG was 1.10 (95% CI: 1.05, 1.14) per 1000 patient–years at risk and of definite OAG was 0.79 (95% CI: 0.75, 0.83) per 1000 patient–years at risk. For both diagnoses, age–specific incidence rates increased markedly in both sexes through age 84 and then declined in those >84. Conclusions:Despite the limitations inherent in estimating disease incidence using a retrospective medical records database, this study provides an initial estimate of the incidence of OAG in the UK.

Keywords: clinical (human) or epidemiologic studies: prevalence/incidence 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×